The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo

The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo

Enterovirus 71 (EV71) causes severe central nervous system infections, leading to cardiopulmonary complications and death in young children. There is an urgent unmet medical need for new pharmaceutical agents to control EV71 infections. Using a multidisciplinary approach, we found that the approved...

Full description

Bibliographic Details
Main Authors: Peijun Ren, Gang Zou, Benjamin Bailly, Shanshan Xu, Mei Zeng, Xinsheng Chen, Liang Shen, Ying Zhang, Patrice Guillon, Fernando Arenzana-Seisdedos, Philippe Buchy, Jian Li, Mark von Itzstein, Qihan Li, Ralf Altmeyer
Format: Article
Language:English
Published: Taylor & Francis Group 2014-01-01
Series:Emerging Microbes and Infections
Subjects:
anti-viral
drug discovery
enterovirus 71
hand, foot and mouth disease
suramin
Online Access:https://www.tandfonline.com/doi/10.1038/emi.2014.60

Internet

https://www.tandfonline.com/doi/10.1038/emi.2014.60

Similar Items